"Efficacy and Safety of Vismodegib" Report Released

The New England Journal of Medicine yesterday released a report on the "Efficacy and Safety of Vismodegib in advanced Basal Cell Carcinoma".

Following a clinical trial for the treatment of basal cell carcinomas in the USA the findings were published yesterday.   Vismodegib is associated with tumor responses in patients with locally advanced or metastatic basal-cell carcinoma.  A summary of the report can be viewed at The New England Journal of Medicine.





 Originally produced by Professor P. A. Farndon, Clinical Geneticist, Jim Costello (deceased) and Margaret Costello.  We are reliant on a team of medical advisors for the clinical content of the website. We are grateful for their continuing support. 
Gorlin Syndrome Group is Registered Charity in the UK - No 1096361 
Gorlin Syndrome community on HealthUnlocked
website security